Commons, Marty

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study to Assess the Wakefulness Promoting Effect, Safety, Tolerability, and Pharmacokinetics (PK) of LML134 in Shift Work Disorder

Phase 2

Terminated

Conditions: Circadian Rhythm Disorders

Interventions: Drug: LML134
Drug: Placebo

First Posted Date: 2017-05-04

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 24

Registration Number: NCT03141086

Locations: 🇺🇸
Novartis Investigative Site, Cincinnati, Ohio, United States

A Bronchoprovocation Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of CSJ117 in Adult Subjects With Mild Atopic Asthma

Phase 1

Completed

Conditions: Asthma

Interventions: Drug: CSJ117
Drug: Placebo Comparator

First Posted Date: 2017-05-03

Last Posted Date: 2021-10-12

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 28

Registration Number: NCT03138811

Locations: 🇩🇪
Novartis Investigative Site, Mainz, Germany

Bronchodilator Effects and Safety of Glycopyrronium Bromide (25 ug and 50 ug o.d.) in Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: NVA237 (glycopyrronium bromide)
Drug: Placebo

First Posted Date: 2017-05-03

Last Posted Date: 2019-01-16

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 148

Registration Number: NCT03137784

Locations: 🇱🇹
Novartis Investigative Site, Klaipeda, Lithuania

SKIPPAIN - Speed of Onset of SecuKinumab-Induced Relief From Pain in Patients With AxIal SpoNdyloarthritis

Phase 3

Completed

Conditions: Spondyloarthritis

Interventions: Biological: AIN457
Drug: AIN457 Placebo

First Posted Date: 2017-05-02

Last Posted Date: 2021-09-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 383

Registration Number: NCT03136861

Locations: 🇬🇧
Novartis Investigative Site, Wolverhampton, United Kingdom

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

Phase 2

Terminated

Conditions: Alzheimers Disease

Interventions: Drug: CNP520 50mg
Drug: CNP520 15mg
Other: Matching placebo

First Posted Date: 2017-04-27

Last Posted Date: 2021-08-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 1145

Registration Number: NCT03131453

Locations: 🇺🇸
Meridien Research, 2300 Maitland center, Pkwy Ste 230, Maitland, Florida, United States
🇺🇸
Syrentis Clinical Research, 1401 N Tustin Ave, Suite 130, Santa Ana, California, United States
🇬🇧
Novartis Investigative Site, London, United Kingdom

and more 33 locations

Study of PK/PD, Safety and Tolerability of LIK066 in Patients With Decreased Renal Function.

Phase 2

Completed

Conditions: Renal Impairment

Interventions: Drug: LIK066

First Posted Date: 2017-04-27

Last Posted Date: 2021-01-05

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 53

Registration Number: NCT03131479

Locations: 🇺🇸
Novartis Investigative Site, Orlando, Florida, United States

Phase III B in Acute Lymphoblastic Leukemia

Phase 3

Completed

Conditions: Acute Lymphoblastic Leukemia

Interventions: Biological: CTL019

First Posted Date: 2017-04-21

Last Posted Date: 2021-07-21

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 69

Registration Number: NCT03123939

Locations: 🇪🇸
Novartis Investigative Site, Esplugues de Llobregat, Barcelona, Spain

Dose Finding Study of TNO155 in Adult Patients With Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Advanced EGFRmutant NonSmallSellLungCancer (NSCLC),KRAS G12-mutant NSCLC,Esophageal SquamousCellCancer (SCC),Head/Neck SCC,Melanoma

Interventions: Drug: TNO155
Drug: TNO155 in combination with EGF816 (nazartinib)

First Posted Date: 2017-04-14

Last Posted Date: 2024-07-18

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 227

Registration Number: NCT03114319

Locations: 🇺🇸
Dana Farber Cancer Center, Boston, Massachusetts, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇨🇳
Novartis Investigative Site, Taipei, Taiwan

and more 2 locations

An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)

Conditions: FLT3-mutated Acute Myeloid Leukemia

First Posted Date: 2017-04-14

Last Posted Date: 2019-10-15

Lead Sponsor: Novartis Pharmaceuticals

Registration Number: NCT03114228

Locations: 🇨🇦
Novartis Investigative Site, Montreal, Quebec, Canada

Study of Single Agent CJM112, and PDR001 in Combination With LCL161 or CJM112 in Patients With Multiple Myeloma

Phase 1

Completed

Conditions: Multiple Myeloma

Interventions: Drug: PDR001
Drug: CJM112
Drug: LCL161

First Posted Date: 2017-04-13

Last Posted Date: 2022-02-09

Lead Sponsor: Novartis Pharmaceuticals

Target Recruit Count: 26

Registration Number: NCT03111992

Locations: 🇺🇸
Mayo Clinic Arizona, Phoenix, Arizona, United States
🇺🇸
Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇪🇸
Novartis Investigative Site, Madrid, Spain

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy